Cadila Healthcare has inked a pact to sell rights of its cholesterol lowering product Zypitamag in the US and Canada markets to Medicure lnc for a total consideration of $7 million. The company has entered into an asset purchase agreement to sell its right, title and interest in Zypitamag, along with applicable registrations and intangible assets relating to the product for US and Canada markets to drug firm Medicure.
Cadila inks pact to sell rights of cholesterol lowering drug in US, Canada to Medicure
Date posted: Tuesday 1 October 2019